Caroline J. Meek is with RTI International, Research Triangle Park, NC. Leah M. Ranney and Sarah D. Kowitt are with the Department of Family Medicine, the Lineberger Comprehensive Cancer Center, and the Center for Health Promotion and Disease Prevention at the University of North Carolina at Chapel Hill. Sonia A. Clark and Kristen L. Jarman are with the Department of Family Medicine at the University of North Carolina at Chapel Hill. Rachel Callanan is with the Public Health Law Center, St. Paul, MN.
Am J Public Health. 2024 Nov;114(S8):S681-S684. doi: 10.2105/AJPH.2024.307722.
To characterize regulatory practices related to nonmedical cannabis warning labels in states across the United States that have legalized retail nonmedical cannabis. In March 2024, we conducted a content analysis of regulations for nonmedical cannabis warning labels required on product packages in 20 states where, as of March 2024, adults could legally purchase nonmedical cannabis in retail environments. For each state, we examined requirements related to warning label content and characteristics. Required warning label content and characteristics varied widely across states. Only 2 states required a warning about mental health risks (10%) and 2 states required a warning for high potency products on risk of psychosis (10%). No states required front-of-package warning placement, only 2 states required rotating warnings (10%), and 4 states required contrasting colors (20%). Warnings were often verbose (mean = 57 words), vague, and had small or no minimum font size. Opportunities exist for states to improve the alignment of their nonmedical cannabis warning label regulations with evidence that has been generated so far in cannabis effects, cannabis warning efficacy, and warning label design. (. 2024;114(S8):S681-S684. https://doi.org/10.2105/AJPH.2024.307722).
描述美国已将非医用大麻零售合法化的各州与非医用大麻警告标签相关的监管实践。 2024 年 3 月，我们对 20 个州的非医用大麻产品包装上所需的非医用大麻警告标签法规进行了内容分析，截至 2024 年 3 月，这些州的成年人可以在零售环境中合法购买非医用大麻。对于每个州，我们都检查了与警告标签内容和特征相关的要求。 各州所需的警告标签内容和特征差异很大。只有 2 个州要求对心理健康风险发出警告（10%），只有 2 个州要求对高效力产品发出关于精神病风险的警告（10%）。没有州要求在包装正面放置警告，只有 2 个州要求轮流发布警告（10%），4 个州要求使用对比色（20%）。警告通常冗长（平均值=57 个单词）、模糊，且最小字体大小很小或没有。 各州有机会根据迄今为止在大麻效应、大麻警告效果和警告标签设计方面产生的证据，调整其非医用大麻警告标签法规。（2024；114(S8):S681-S684。https://doi.org/10.2105/AJPH.2024.307722）。
